For heart failure patients with reduced EF, guideline-directed medical therapy (GDMT) must be initiated, which includes β-blockers, renin-angiotensin blockade including angiotensin receptor neprilysin inhibition, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors [3,22]. This evidence concerns the gene SLC5A2 and heart failure.